Roberto Bellini, Bellus Health CEO

September 13, 2021 10:24 AM EDTUpdated September 14, 06:23 AM

Bellus says its Merck cough rival passed a PhIIb test after earlier flop, but investors can't make up their minds

Max Gelman

Senior Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

FDA approves Moderna’s next-gen Covid vaccine, with limits on most healthy people

Summit says bispecific misses overall survival in closely-watched lung cancer study

Summit’s disappointing survival readout raises stakes for full data

Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer

Arvinas, Pfizer's PROTAC in breast cancer no better than oral SERDs

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation